Business
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMT...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Corporate UpdateCalgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") The Company is pleased to announce that the previously disclosed proposed consolidation of the common shares of the Company on the basis of twenty pre-consolidation shares for one post-consolidation share (the \"Consolidation\") will take effect, subject to final acceptance by the TSX Venture Exchange, on or about December 30, 2020 under new CUSIP number 423694306. There will be no name change or trading symbol change in conjunction with the Consolidation. The Consolidation was approved by the Company's shareholders at the Annual General Meeting held on May 6, 2020. Following the Consolidation, the total issued and outstanding common shares of the Company will be approximately 46,368,985. ABOUT HEMOSTEMIXHemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled \"Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up\" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com.For further information, please contact:Thomas Smeenk, President, CEO & FounderSuite 1150, 707 - 7th Avenue S.W., Calgary, Alberta T2P 3H6Phone: 905-580-4170Neither the TSX Venture Exchange nor i...